How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Strontium-89 Chloride Injection Market
- By Application: Bone Metastases Pain Palliation, Osteoblastic Bone Lesions, Palliative Care in Prostate Cancer, Palliative Care in Breast Cancer, Palliative Care in Lung Cancer
- By End User: Hospitals, Oncology Clinics, Specialty Cancer Centers, Ambulatory Surgical Centers, Research Institutes
- By Route of Administration: Intravenous Injection
- By Dosage Form: Injectable Solution
- By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Direct Sales
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Bone Metastases Pain Palliation leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.169 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.177 →
Full report · locked preview
Everything inside the Strontium-89 Chloride Injection Market report
A complete, evidence-based study - 12 chapters and 117 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Application 5
End User 5
Route of Administration 1
Dosage Form 1
Distribution Channel 3
Companies profiled
Bayer AG
Lantheus Medical Imaging Inc.
ITM Isotopen Technologien München AG
Nordion Inc. (a Sotera Health company)
Curium Pharma
Advanced Accelerator Applications (AAA) - a Novartis company
Nordion (a Sotera Health company)
Eckert & Ziegler AG
Lantheus Holdings Inc.
Nordion Inc.
Curium US LLC
ITM Isotopes GmbH
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Lantheus Medical Imaging Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →ITM Isotopen Technologien München AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nordion Inc. (a Sotera Health company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Curium Pharma
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Advanced Accelerator Applications (AAA) - a Novartis company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Nordion (a Sotera Health company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Eckert & Ziegler AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Lantheus Holdings Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nordion Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Curium US LLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →ITM Isotopes GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Bayer Healthcare Pharmaceuticals
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lantheus Medical Imaging
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,368M by 2033 · 11.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bone Metastases Pain Palliation48.4
- Osteoblastic Bone Lesions13.7
- Palliative Care in Prostate Cancer12.5
- Palliative Care in Breast Cancer16.0
- Palliative Care in Lung Cancer9.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$883.3M → $2,252M · 12.4%
Europe$615.6M → $1,544M · 12.2%
Asia Pacific$562.1M → $1,436M · 12.4%
Latin America$348.0M → $896.5M · 12.6%
Middle East and Africa$267.7M → $685.7M · 12.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.392026
11.402027
11.412028
11.432029
11.442030
11.462031
11.482032
11.492033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bayer AG15.1
- Lantheus Medical Imaging Inc.13.2
- ITM Isotopen Technologien München AG14.0
- Nordion Inc. (a Sotera Health company)7.5
- Curium Pharma10.2
- Advanced Accelerator Applications (AAA) - a Novartis company12.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Application20.7%
End User27.2%
Route of Administration15.5%
Dosage Form21.3%
Distribution Channel15.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.0
- Europe22.7
- Asia Pacific21.1
- Latin America13.2
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bayer AG | 86 | 76 | 92 | 81 | 74 | 95 | 84 |
| Lantheus Medical Imaging Inc. | 74 | 69 | 78 | 76 | 71 | 81 | 75 |
| ITM Isotopen Technologien München AG | 70 | 77 | 68 | 63 | 75 | 75 | 71 |
| Nordion Inc. (a Sotera Health company) | 80 | 75 | 79 | 74 | 65 | 63 | 73 |
| Curium Pharma | 55 | 56 | 55 | 62 | 55 | 68 | 59 |
| Advanced Accelerator Applications (AAA) - a Novartis company | 64 | 56 | 58 | 54 | 59 | 50 | 57 |
| Nordion (a Sotera Health company) | 45 | 44 | 66 | 61 | 49 | 58 | 54 |
| Eckert & Ziegler AG | 44 | 54 | 43 | 48 | 60 | 46 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bayer AG
- Lantheus Medical Imaging Inc.
- ITM Isotopen Technologien München AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bayer AG | ✓ | ◐ | ◐ | ✓ | ◐ | ◐ |
| Lantheus Medical Imaging Inc. | ◐ | − | ◐ | − | ◐ | ✓ |
| ITM Isotopen Technologien München AG | ◐ | ◐ | ◐ | − | ◐ | ✓ |
| Nordion Inc. (a Sotera Health company) | ✓ | ◐ | ◐ | ◐ | − | ◐ |
| Curium Pharma | − | − | − | − | − | − |
| Advanced Accelerator Applications (AAA) - a Novartis company | ◐ | ◐ | − | − | − | − |
| Nordion (a Sotera Health company) | ◐ | − | ◐ | − | ◐ | − |
| Eckert & Ziegler AG | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bayer AG84
2Lantheus Medical Imaging Inc.75
3Nordion Inc. (a Sotera Health company)73
4ITM Isotopen Technologien München AG71
5Curium Pharma59
6Advanced Accelerator Applications (AAA) - a Novartis company57
7Nordion (a Sotera Health company)54
8Eckert & Ziegler AG49
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Bayer AG
Challenger3
Strong scale, closing on the leaders.
Lantheus Medical Imaging Inc.ITM Isotopen Technologien München AGNordion Inc. (a Sotera Health company)
Contender2
Focused players with pockets of strength.
Curium PharmaAdvanced Accelerator Applications (AAA) - a Novartis company
Niche2
Specialists in a single segment or region.
Nordion (a Sotera Health company)Eckert & Ziegler AG
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across Strontium-89 Chloride Injection Market — a $57M beachhead inside a $1.02B market.
Beachhead (SOM)$57Mobtainable near-term
Serviceable (SAM)$388Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Bone Metastases Pain Palliation
Best fit — highest urgency & budget in Application.
Economic buyer75 fit
Osteoblastic Bone Lesions
Strong fit — clear ROI and a fast path to value.
End user67 fit
Palliative Care in Prostate Cancer
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel26%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Strontium-89 Chloride Injection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified25%
Evaluation11%
Closed-won6%
$11.5KCAC
$56KLTV
4.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Strontium-89 Chloride Injection Market is a resilient opportunity — $1.92B by 2033, compounding at 5.0%.
TAM · 2025$1.30Btoday
TAM · 2033$1.92Bforecast
CAGR5.0%2027–2033
Cumulative$14.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.92BTotal addressable market
SAM$674MServiceable available market
SOM$132MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.0% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.92BLarge & growingTAM by 2033 at 5.0% CAGR
$674MServiceable nowreachable with today’s model
$132MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.50BBear3.3% CAGR
$1.92BBase5.0% CAGR
$2.46BBull6.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Strontium-89 Chloride Injection Market — a $7.83B market by 2033. Plan: grow share from 7.3% to 14.8%.
Market size · 2033$7.83Btotal addressable
Market CAGR8.0%2027–2033
Target share14.8%from 7.3% today
Revenue ambition$1.16Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.3% | 14.8% | On track |
| Revenue | $589M | $1.16B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 35.2% | 40.7% | Behind |
| Customer retention | 85.4% | 92.3% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $152M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Strontium-89 Chloride Injection Market conversation — a $3.80B market you can size, segment and defend in minutes.
Market size · 2033$3.80Btotal opportunity
Growth7.1%CAGR to 2033
Addressable buyers1,006+accounts in scope
Typical ROI5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5×return on cost, year one
< 3 mopayback period
$82K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Bayer AGLantheus Medical Imaging Inc.ITM Isotopen Technologien München AGNordion Inc. (a Sotera Health company)Curium PharmaAdvanced Accelerator Applications (AAA) - a Novartis companyNordion (a Sotera Health company)Eckert & Ziegler AG+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Strontium-89 Chloride Injection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Strontium-89 Chloride Injection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Strong Laser Oral 3D Camera Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportStroke Therapeutics Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportStroke Testing Biomarkers Market
Market size, share, segmentation and regional forecast.
$982M market · 2025 base year
View reportStroke Telemedicine Services Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportStroke-physiological Saline Solution Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStroke Management Device Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportStroke Diagnostics Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportStrip Warmer Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportStrip Test Handler Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportStrip Readers Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportStretch Mark Treatment Product Market
Market size, share, segmentation and regional forecast.
$569M market · 2025 base year
View reportStretch Marks Removal Products Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.